Vilin Bio Med Voluntarily Adopts Main Board Corporate Governance Reporting Standards
Vilin Bio Med Ltd 路 Others (Uncategorized) 路 27 Oct 2026, 6:51 pm
Vilin Bio Med Voluntarily Adopts Main Board Corporate Governance Reporting Standards Vilin Bio Med Limited submitted its Integrated Corporate Governance Report for the quarter ended 30th Sep'26 on a voluntary basis. Although listed on NSE Emerge and exempt under Regulation 15(2)(b) of SEBI LODR Regulations, the company adopted Main Board governance norms. The board confirmed full compliance across committee compositions, reported zero investor grievances, and noted no cyber security breaches during the period. Additionally, the filing affirmed 100% holdings in unlisted entities Axia Pharma Private Limited and Vilo Speciality Pharma Private Limited.
Original exchange filing (PDF)
More announcements from Vilin Bio Med Ltd
- Vilin Bio Med Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- VILIN BIO MED LIMITED has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 14 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 14 Nov 2026
- Vilin Bio Med Limited has submitted the Exchange a copy Srutinizers report of Court Convened General Meeting held on October 15, 2026. Further, the company has informed the Exchange regarding voting results. 路 16 Oct 2026
- Vilin Bio Med Limited has informed the Exchange regarding Proceedings of Court Convened General Meeting held on October 15, 2026 路 15 Oct 2026
- Vilin Bio Med Limited has informed the Exchange regarding Outcome of Board Meeting held on September 15, 2026. 路 16 Sept 2026
- Vilin Bio Med Limited has informed the Exchange regarding 'General Updates'. 路 15 Sept 2026
- Vilin Bio Med Limited has informed the Exchange regarding 'General Updates'. 路 15 Sept 2026
